Irbegen Plus

Per 150/12.5 mg FC tab Irbesartan 150 mg, hydrochlorothiazide 12.5 mg. Per 300/12.5 mg FC tab Irbesartan 300 mg, hydrochlorothiazide 12.5 mg. Per 300/25 mg FC tab Irbesartan 300 mg, hydrochlorothiazide 25 mg

High BP, when treatment w/ irbesartan or hydrochlorothiazide alone did not provide adequate control of BP.

1 tab daily, at about the same time each day.

May be taken with or without food: Swallow w/ a sufficient amount of fluid.

Hypersensitivity to irbesartan, hydrochlorothiazide or any other sulfonamide-derived medicines. Difficulty in producing urine; persistent high Ca or low K levels in the blood; severe liver or kidney problems. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Pregnancy for >3 mth.

Patients w/ excessive vomiting or diarrhea; kidney, heart or liver problems; recent kidney transplant; DM; hypoglycemia, particularly during DM treatment; SLE; primary aldosteronism; skin cancer or development of an unexpected skin lesion during treatment; breathing or lung problems following previous hydrochlorothiazide intake; low-salt diet; signs indicative of excessive effect of hydrocholorothiazide; increased skin sensitivity to the sun w/ symptoms of sunburn occurring more quickly than normal; intolerance to some sugars. Increased risk of non-melanoma skin cancer w/ hydrochlorothiazide, particularly w/ long-term use of high doses. Protect skin from sun exposure & UV rays during treatment. Regularly check the skin for any new lesions. Risk of idiosyncratic reaction, which may result in choroidal effusion, secondary acute angle-closure glaucoma &/or acute transient myopia. Dual blockade of renin-angiotensin-aldosterone system through combined use of ACE-inhibitors, ARBs or aliskiren is not recommended. Check kidney function, BP, & electrolyte levels (eg, K) in the blood at regular intervals. +ve result in anti-doping test. Occasional dizziness or weariness may occur during treatment. Not recommended in early pregnancy & in breast-feeding women. Do not use in childn & adolescents <18 yr.

Nausea/vomiting, abnormal urination, fatigue, dizziness, increased creatine kinase, BUN, creatinine.

Lithium-containing prep should not be taken. Adjust dose &/or take precaution w/ concomitant ACE inhibitor or aliskiren. Higher frequency of adverse events w/ combined use of ACE inhibitors, ARBs or aliskiren. Blood checks may be necessary w/ concomitant K supplements; salt substitutes containing K; K-sparing medicines or other diuretics; some laxatives; medicines for gout; therapeutic vit D supplements; medicines to control heart rhythm; antidiabetics; carbamazepine. Potential interaction w/ other antihypertensives, steroids, anticancer drugs, pain killers, arthritis medicines, colestyramine, colestipol resins. Risk of orthostatic hypotension w/ alcohol.

Angiotensin II Antagonists / Diuretics

C09DA04 - irbesartan and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.

P₁S₁S₃